TOKYO, January 6, 2016 - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Chugai and Novartis Pharma K.K. have agreed to terminate the agreement regarding co-marketing of aromatase ...
To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC). Thirteen oestrogen receptor-positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results